SCHEMBL3970120

SCHEMBL3970120

CC(=O)O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)O[C@H](CO)[C@H](O)[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD69 Q07108 2/20 0.46
LGALS3 P17931 4/20 0.43
LGALS8 O00214 4/20 0.43
LGALS4 P56470 2/20 0.43
AMY2A P04746 3/20 0.43
LGALS9 O00182 1/20 0.43
LGALS1 P09382 1/20 0.43
LGALS7; LGALS7B P47929 1/20 0.43
FGF1 P05230 1/20 0.40
SLC28A3 Q9HAS3 1/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 2/20 0.39
MGAM O43451 2/20 0.39
AMY1A P0DUB6 1/20 0.39
SI P14410 1/20 0.39
CNR1 P21554 1/20 0.39
PTGS1 P23219 1/20 0.39
PDE4A P27815 1/20 0.39
PDE3A Q14432 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920478 0.97 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL15720609 0.97 LGALS3 (0.47) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL15709547 0.96 LGALS3 (0.46) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL15226769 0.96 LGALS3 (0.46) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL17654900 0.95 LGALS3 (0.49) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL14616535 0.95 LGALS3 (0.49) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL15546804 0.93 LGALS8 (0.43) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL15545709 0.93 CD69 (0.47) CD69LGALS3LGALS8LGALS4LGALS9
SCHEMBL17767385 0.92 LGALS8 (0.44) CD69LGALS3LGALS8LGALS4AMY2A
SCHEMBL2237219 0.90 LGALS8 (0.49) CD69LGALS3LGALS8LGALS4AMY2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200108127-A1 HYPOTONIC COMPOSITION FOR FAT DECOMPOSITION AND METHOD FOR PREPARING SAME LEE KYOUNG LACK (KR) 2020-04-09 US claimed
US-20250144021-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2025-05-08 US disclosed
US-12226527-B2 Gel formulations for local drug release TECHNICAL UNIVERSITY OF DENMARK (DK) 2025-02-18 US disclosed
CN-115501172-A Gel formulations for topical drug delivery 丹麦技术大学 2022-12-23 CN disclosed
US-20220339285-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2022-10-27 US disclosed
CN-107249570-B Gel formulations for topical drug delivery 丹麦技术大学 2022-08-09 CN disclosed
US-11331396-B2 Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility TECHNICAL UNIVERSITY OF DENMARK (DK) 2022-05-17 US disclosed
EP-3982922-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE Technical University of Denmark (DK) 2022-04-20 EP disclosed
US-20210386669-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2021-12-16 US disclosed
US-11065201-B2 Gel formulations for local drug release TECHNICAL UNIVERSITY OF DENMARK (DK) 2021-07-20 US disclosed
US-20150152462-A1 Carbohydrate Esters as Inducers for Gene Expression SOPHORO BIOTECHNOLOGIES, LLC (US) 2015-06-04 US disclosed
EP-2875143-A1 CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION Sophoro Biotechnologies LLC (US) 2015-05-27 EP disclosed
CN-104471071-A Sugar esters as inducers of gene expression SOPHORO BIOTECHNOLOGIES LLC 2015-03-25 CN disclosed
WO-2014015179-A1 CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION SOPHORO BIOTECHNOLOGIES, LLC (US) 2014-01-23 WO disclosed
US-7507675-B2 Silicon substrate is irradiated to produce silicon oxide; reacted with 1-alkene or alkylne; Field Effect Transistor (FET) structures, gate of FET being formed by functionalized organic monolayer containing oligosaccharides or oligopeptides, capable of interacting with biological substance; biosesors ASML NETHERLANDS B.V. (NL) 2009-03-24 US disclosed
US-20070178707-A1 Device manufacturing method and device ASML NETHERLANDS B.V. (NL) 2007-08-02 US disclosed
WO-2005001461-A2 BIOSENSOR AND METHOD OF PREPARATION ASML NETHERLANDS B.V. (NL) 2005-01-06 WO disclosed
EP-0071598-A4 THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS. BAZZANO GAIL S 1983-06-08 EP disclosed
EP-0071598-A1 THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FURBEARING ANIMALS. BAZZANO GAIL S 1983-02-16 EP disclosed
WO-1982002833-A1 THE USE OF RETINOIDS AND THEIR DERIVATIVES TO INCREASE THE RATE OF GROWTH OF HUMAN SCALP HAIR AND TO INCREASE THE RATE OF GROWTH OF FUR IN CERTAIN FUR-BEARING ANIMALS BAZZANO GAIL SANSONE 1982-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331396-B2 Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility HEXB, GLB1, GOLT1B CD69 1436/4885LGALS3 64/4885LGALS8 243/4885
US-11065201-B2 Gel formulations for local drug release TREH, GALE, SLC2A8 CD69 1327/4885LGALS3 40/4885LGALS8 19/4885
US-20250144021-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TREH, GALE, SLC2A8 CD69 1327/4885LGALS3 40/4885LGALS8 19/4885
US-20210386669-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TREH, GALE, SLC2A8 CD69 1327/4885LGALS3 40/4885LGALS8 19/4885
US-12226527-B2 Gel formulations for local drug release TREH, GALE, SLC2A8 CD69 1327/4885LGALS3 40/4885LGALS8 19/4885
US-20220339285-A1 DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE LIPA, LIPE, CEL CD69 1575/4885LGALS3 257/4885LGALS8 190/4885
US-20150152462-A1 Carbohydrate Esters as Inducers for Gene Expression HSD17B14, MGAM, ATF4 CD69 386/4885LGALS3 738/4885LGALS8 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.